Ignite Creation Date:
2025-12-25 @ 2:27 AM
Ignite Modification Date:
2025-12-29 @ 7:29 AM
Study NCT ID:
NCT05743634
Status:
COMPLETED
Last Update Posted:
2023-02-24
First Post:
2023-02-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines
Sponsor:
Chongqing Claruvis Pharmaceutical Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03-22
Start Date Type:
ACTUAL
Primary Completion Date:
2023-02-13
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-02-13
Completion Date Type:
ACTUAL
First Submit Date:
2023-02-15
First Submit QC Date:
None
Study First Post Date:
2023-02-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-02-15
Last Update Post Date:
2023-02-24
Last Update Post Date Type:
ACTUAL